Photocure Asa Drug Patent Portfolio
Photocure Asa owns 1 orange book drug protected by 7 US patents Given below is the list of Photocure Asa's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11235168 | Method of photodynamic therapy (PDT) for bladder cancer | 04 Jan, 2038 | Active |
US10556010 | Neoadjuvant therapy for bladder cancer | 19 Dec, 2036 | Active |
US11311620 | Neoadjuvant therapy for bladder cancer | 19 Dec, 2036 | Active |
US7348361 | Solution for diagnosing or treating tissue pathologies | 22 Apr, 2019 | Expired |
US7530461 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy | 11 Jan, 2017 | Expired |
US6034267 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy | 08 Mar, 2016 | Expired |
US7247655 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy | 08 Mar, 2016 | Expired |
Latest Legal Activities on Photocure Asa's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Photocure Asa.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 4th Yr, Small Entity | 11 Aug, 2023 | US10556010 |
Recordation of Patent Grant Mailed
Critical
| 26 Apr, 2022 | US11311620 |
Patent Issue Date Used in PTA Calculation
Critical
| 26 Apr, 2022 | US11311620 |
Email Notification
Critical
| 07 Apr, 2022 | US11311620 |
Issue Notification Mailed
Critical
| 06 Apr, 2022 | US11311620 |
Dispatch to FDC | 22 Mar, 2022 | US11311620 |
Application Is Considered Ready for Issue
Critical
| 22 Mar, 2022 | US11311620 |
Issue Fee Payment Received
Critical
| 21 Mar, 2022 | US11311620 |
Issue Fee Payment Verified
Critical
| 21 Mar, 2022 | US11311620 |
Recordation of Patent Grant Mailed
Critical
| 01 Feb, 2022 | US11235168 |
Patent Issue Date Used in PTA Calculation
Critical
| 01 Feb, 2022 | US11235168 |
Email Notification
Critical
| 13 Jan, 2022 | US11235168 |
Issue Notification Mailed
Critical
| 12 Jan, 2022 | US11235168 |
Electronic Review
Critical
| 22 Dec, 2021 | US11311620 |
Email Notification
Critical
| 22 Dec, 2021 | US11311620 |
Photocure Asa's Family Patents
Photocure Asa drugs have patent protection in a total of 17 countries. It's US patent count contributes only to 15.6% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Photocure Asa Drug List
Given below is the complete list of Photocure Asa's drugs and the patents protecting them.
1. Cysview Kit
Cysview Kit is protected by 7 patents, out of which 4 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11235168 | Method of photodynamic therapy (PDT) for bladder cancer |
04 Jan, 2038
(13 years from now)
| Active |
US10556010 | Neoadjuvant therapy for bladder cancer |
19 Dec, 2036
(12 years from now)
| Active |
US11311620 | Neoadjuvant therapy for bladder cancer |
19 Dec, 2036
(12 years from now)
| Active |
US7348361 | Solution for diagnosing or treating tissue pathologies |
22 Apr, 2019
(5 years ago)
| Expired |
US7530461 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
11 Jan, 2017
(7 years ago)
| Expired |
US6034267 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
08 Mar, 2016
(8 years ago)
| Expired |
US7247655 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
08 Mar, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cysview Kit's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List